Pomerantz Law Firm Launches Class Action Lawsuit Against Novo Nordisk A/S Over Alleged Securities Fraud
Pomerantz Law Firm Launches Class Action Lawsuit Against Novo Nordisk A/S Over Alleged Securities Fraud
Pomerantz LLP, a distinguished law firm with a strong reputation in corporate and securities litigation, has officially initiated a class action lawsuit against Novo Nordisk A/S (NASDAQ: NVO), alleging serious misconduct related to securities fraud. This action comes in light of recent disclosures regarding a key clinical trial that raised concerns among investors.
The lawsuit pertains to the results of the REDEFINE-1 trial, where Novo Nordisk reported that its product, CagriSema, achieved an average weight loss of only 22.7% after 68 weeks. This figure fell short of investor expectations, especially against the backdrop of what was previously promoted. The investigation revealed that the clinical trial's protocol contained certain undisclosed
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.